DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR REGORAFENIB
» See Plans and Pricing
All Clinical Trials for regorafenib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01002378 | The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib | Completed | Bayer | Phase 1 | 2009-10-01 | An open label, three way crossover study to determine the effect of a high fat breakfast or a low fat breakfast on the pharmacokinetics of a single dose of regorafenib. |
| NCT01068769 | Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | Active, not recruiting | Bayer | Phase 2 | 2010-02-01 | The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study. |
| NCT01068769 | Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | Active, not recruiting | Brigham and Women's Hospital | Phase 2 | 2010-02-01 | The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study. |
| NCT01068769 | Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | Active, not recruiting | Fox Chase Cancer Center | Phase 2 | 2010-02-01 | The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study. |
| NCT01068769 | Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor | Active, not recruiting | Massachusetts General Hospital | Phase 2 | 2010-02-01 | The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for regorafenib
Condition Name
Clinical Trial Locations for regorafenib
Trials by Country
Clinical Trial Progress for regorafenib
Clinical Trial Phase
Clinical Trial Sponsors for regorafenib
Sponsor Name
